The GeneStrat blood-based panel from Biodesix Inc, Boulder, Colo, is now able to detect EML4-ALK gene fusions in addition to BRAF, EGFR sensitizing, EGFR T790M, and KRAS gene mutations. GeneStrat is a noninvasive, blood-based test analyzing circulating tumor DNA and RNA, designed to provide accurate results in 72 hours for newly diagnosed non-small cell lung cancer (NSCLC) patients. Based on NSCLC patient samples, GeneStrat is highly sensitive and specific, with data supporting concordance with fluorescence in situ hybridization, polymerase chain reaction, and tissue-based methods. GeneStrat can be reflexed to VeriStrat, a blood-based proteomic test for EGFR-negative patients, used to identify more aggressive tumor growth and inform likely patient benefit from treatment. For more information, visit Biodesix.